Durvalumab with or without tremelimumab for patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a systematic review and meta-analysis

Durvalumab with or without tremelimumab for patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a systematic review and meta-analysis

ObjectiveHead and neck squamous cell carcinoma (HNSCC) ranks as the sixth most prevalent cancer worldwide, significantly impacting patients’ quality of life. Immune checkpoint inhibitors (ICI) have been employed in the treatment of recurrent/metastatic (R/M)-HNSCC patients. This meta-analysis aims t...

Full description

Bibliographic Details
Main Authors:	Xiao Han, Haidong Zhang, Kai Sun, Jing Li, Wanjuan Wu, Kai Liu, Zhenkun Yu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-01-01
Series:	Frontiers in Immunology
Subjects:	durvalumab immunotherapy meta-analysis recurrent or metastatic HNSCC tremelimumab
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1302840/full

Similar Items

Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma
by: Houda Bahig, et al.
Published: (2019-01-01)

Adverse Events and Tolerability of Combined Durvalumab and Tremelimumab versus Durvalumab Alone in Solid Cancers: A Systematic Review and Meta-Analysis
by: Omar Fahmy, et al.
Published: (2022-05-01)

Plasma Growth Hormone as a Prognostic Biomarker to Durvalumab and Tremelimumab in Patients with Advanced Hepatocellular Carcinoma
by: Chamseddine S, et al.
Published: (2024-03-01)

Activity of murine surrogate antibodies for durvalumab and tremelimumab lacking effector function and the ability to deplete regulatory T cells in mouse models of cancer
by: Darren J. Schofield, et al.
Published: (2021-01-01)

First-line tremelimumab plus durvalumab and chemotherapy versus chemotherapy alone for metastatic non-small cell lung cancer: a cost-effectiveness analysis in the United States
by: Wenjie Liu, et al.
Published: (2023-07-01)

Remission of an Intracardiac Melanoma Metastasis after Tremelimumab Therapy
by: Sebastian Spethmann, et al.
Published: (2014-02-01)

Hyperprogressive Disease After Combined Anti-PD-L1 and Anti-CTLA-4 Immunotherapy for MSI-H/dMMR Gastric Cancer: A Case Report
by: Romain Varnier, et al.
Published: (2021-09-01)

Identification of characteristics predictive of long-term survival with durvalumab or durvalumab plus tremelimumab in metastatic urothelial carcinoma
by: Marie Alt, et al.
Published: (2023-09-01)

Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma
by: Faiena I, et al.
Published: (2018-01-01)

Prioritized Requirements for First-Line Systemic Therapy for Hepatocellular Carcinoma: Broad Benefit with Less Toxicity
by: Masatoshi Kudo
Published: (2023-01-01)

Combined immune checkpoint inhibition with durvalumab and tremelimumab with and without radiofrequency ablation in patients with advanced biliary tract carcinoma
by: Cecilia Monge, et al.
Published: (2024-02-01)

Clinical Indicators for Long-Term Survival with Immune Checkpoint Therapy in Advanced Hepatocellular Carcinoma
by: Monge C, et al.
Published: (2021-05-01)

Phimosis: A rare complication of immunotherapy with durvalumab
by: Luis Gabriel Vázquez-Lavista, et al.
Published: (2020-11-01)

Immunotherapy for Stage III NSCLC: Durvalumab and Beyond
by: Fitzpatrick O, et al.
Published: (2021-11-01)

Durvalumab induced sarcoid‐like pulmonary lymphadenopathy
by: Emma Sanderson, et al.
Published: (2020-04-01)

Safety and efficacy of durvalumab (MEDI4736) in various solid tumors
by: Yang H, et al.
Published: (2018-07-01)

Consolidation treatment of durvalumab after chemoradiation in real‐world patients with stage III unresectable non‐small cell lung cancer
by: Chia‐Hsun Chu, et al.
Published: (2020-06-01)

Retinal Vasculitis Secondary to Durvalumab
by: Antonio R. Andrade, et al.
Published: (2020-05-01)

Immunotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
by: Ronan W. Hsieh, et al.
Published: (2021-09-01)

Durvalumab-associated generalized morphea with overlapping vitiligo
by: Julianna Martel, MD, et al.
Published: (2022-12-01)

Strongyloides—An uncommon cause of eosinophilia whilst on durvalumab
by: Gaik Tin Quah, et al.
Published: (2022-10-01)

Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment
by: Jean-David Fumet, et al.
Published: (2020-08-01)

Longitudinal extensive transverse myelitis after chemoradiation therapy with durvalumab, a rare complication: case report
by: Travis Moodie, et al.
Published: (2022-03-01)

Severe Radiation-Induced Lymphopenia Attenuates the Benefit of Durvalumab After Concurrent Chemoradiotherapy for NSCLC
by: Wang Jing, MD, et al.
Published: (2022-09-01)

Development and validation of a fourteen- innate immunity-related gene pairs signature for predicting prognosis head and neck squamous cell carcinoma
by: Fujun Zhang, et al.
Published: (2020-10-01)

Combination of Durvalumab and Chemotherapy to Potentially Convert Unresectable Stage IV Penile Squamous Cell Carcinoma to Resectable Disease: A Case Report
by: Hao Xiang Chen, et al.
Published: (2022-12-01)

Radiation pneumonitis in lung cancer patients treated with chemoradiation plus durvalumab
by: Narek Shaverdian, et al.
Published: (2020-07-01)

Roles of E2F family members in the diagnosis and prognosis of head and neck squamous cell carcinoma
by: Yaoxu Li, et al.
Published: (2023-02-01)

Association Between the Early Discontinuation of Durvalumab and Poor Survival in Patients With Stage III NSCLC
by: Narek Shaverdian, MD, et al.
Published: (2021-07-01)

RADIANCE – Radiochemotherapy with or without Durvalumab in the treatment of anal squamous cell carcinoma: A randomized multicenter phase II trial
by: Daniel Martin, et al.
Published: (2020-07-01)

Identification and validation of a novel tumor driver gene signature for diagnosis and prognosis of head and neck squamous cell carcinoma
by: Shixian Liu, et al.
Published: (2022-10-01)

Exploratory analysis to predict pneumonitis during durvalumab consolidation therapy for patients with locally advanced non‐small cell lung cancer from proteomic profiling of circulating extracellular vesicles
by: Masahiro Torasawa, et al.
Published: (2023-10-01)

Exploring the Molecular Players behind the Potentiation of Chemotherapy Effects by Durvalumab in Lung Adenocarcinoma Cell Lines
by: Marika Saar, et al.
Published: (2023-05-01)

Case Report: Acute Myocarditis Due to PD-L1 Inhibitor Durvalumab Monotherapy in a Patient With Lung Squamous Cell Carcinoma
by: Bo Zhou, et al.
Published: (2022-06-01)

Symptomatic Pneumonitis With Durvalumab After Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC
by: Johan F. Vansteenkiste, MD, PhD, et al.
Published: (2024-03-01)

Unusual radiologic manifestation of pseudoprogression in pulmonary metastases after durvalumab treatment in metastatic bladder urothelial cancer
by: Eun Young Kim, et al.
Published: (2019-04-01)

Exploring causes and consequences of early discontinuation of durvalumab after chemoradiotherapy for non-small cell lung cancer
by: Michael Pennock, et al.
Published: (2023-07-01)

Various clinical presentations of uveitis associated with durvalumab treatment
by: Vrabic Nika, et al.
Published: (2022-04-01)

Safety and tolerability of first‐line durvalumab with tremelimumab and chemotherapy in esophageal squamous cell carcinoma
by: Dae Ho Lee, et al.
Published: (2023-08-01)

Destroyed lung due to sustained inflammation after chemoradiotherapy followed by durvalumab
by: Kageaki Taima, et al.
Published: (2020-07-01)